Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00432172 ("A Randomized Multicenter Phase II Trial to Evaluate the Effectiveness of Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients"), which is not on this map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"A Randomized Multicenter Phase II Trial to Evaluate the Effectiveness of Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients"
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.Breast cancer research : BCR · 2019Trial
- Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer.NPJ breast cancer · 2026Article
- Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results.NPJ breast cancer · 2026Article
- Cell-cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer.PloS one · 2026Article
- Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications.NPJ breast cancer · 2025Article
- Transcriptomic profiles of endocrine-resistant breast cancer.BMC cancer · 2025Article
- Alternative splicing generates HER2 isoform diversity underlying antibody-drug conjugate resistance in breast cancer.Genome research · 2025Article
- Deciphering the transcriptomic landscape of early HRCancer communications (London, England) · 2025Article
- Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer.Cancers · 2025Review
- Multimodal data integration in early-stage breast cancer.Breast (Edinburgh, Scotland) · 2025Review
- Gestational breast cancer: distinctive molecular and clinico-epidemiological features.Journal of mammary gland biology and neoplasia · 2024Observational
- Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.Nature communications · 2024Article
- Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer.ESMO open · 2024Review
- The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer.Journal of personalized medicine · 2023Review
- Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.International journal of molecular sciences · 2022Article
- Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.NPJ breast cancer · 2021Article
- Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 1 institution in 1 country.
Aleix PratDepartment of Medical Oncology, Hospital Clínic i Provincial, Barcelona, Spain. alprat@clinic.ub.es.
Ana LluchDepartment of Medical Oncology, Valencia University Hospital, Valencia, Spain.
Arran K TurnbullUniversity of Edinburgh Cancer, Research UK Centre, Edinburgh.
Anita K DunbierDepartment of Biochemistry, University of Otago, Dunedin, New Zealand.
Lourdes CalvoDepartment of Medical Oncology, A Coruña University Hospital Complex, A Coruña, Spain.
Joan AlbanellDepartment of Medical Oncology, Hospital del Mar Medical Research Institute-IMIM and Pompeu Fabra University, Barcelona, Spain.
Juan de la Haba-RodríguezDepartment of Medical Oncology, Biomedical Research Institute-IMIBIC, Reina Sofía Hospital Complex, Córdoba, Spain.
Angels ArcusaDepartment of Medical Oncology, Consorci Sanitari de Terrassa, Barcelona, Spain.
José Ignacio ChacónDepartment of Medical Oncology, Virgen de la Salud Hospital, Toledo, Spain.
Pedro Sánchez-RoviraDepartment of Medical Oncology, Jaén Hospital Complex, Jaen, Spain.
Arrate PlazaolaDepartment of Medical Oncology, Onkologikoa, Donostia, Spain.
Montserrat MuñozDepartment of Medical Oncology, Hospital Clínic i Provincial, Barcelona, Spain.
Laia ParéTranslational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Nuria RibellesDepartment of Medical Oncology, Virgen de la Victoria University Hospital, Málaga, Spain.
Begoña JimenezDepartment of Medical Oncology, Virgen de la Victoria University Hospital, Málaga, Spain.
Abdul Aziz Bin AiderusUniversity of Edinburgh Cancer, Research UK Centre, Edinburgh.
Rosalía CaballeroGEICAM (Spanish Breast Cancer Research Group), Madrid, Spain.
Barbara AdamoDepartment of Medical Oncology, Hospital Clínic i Provincial, Barcelona, Spain.
Mitch DowsettAcademic Department of Biochemistry, Royal Marsden Foundation Trust, London, United Kingdom.
Eva CarrascoGEICAM (Spanish Breast Cancer Research Group), Madrid, Spain.
Miguel MartínInstituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain.
J Michael DixonUniversity of Edinburgh Cancer, Research UK Centre, Edinburgh.
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Emilio AlbaDepartment of Medical Oncology, Virgen de la Victoria University Hospital, Málaga, Spain.
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ES
Funding
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHARLES M PEROU · 1992 to 2026
$59.3MTherapeutic Targeting of Breast Cancer Tumor Initiating CellsR01CA148761 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, ROSEN, JEFFREY MARK · 2010 to 2025
$6.5MNCI NIH HHS P50 CA058223NCI NIH HHS R01 CA148761
Abstract
PubMed holds no abstract for this paper.
Indexed as
PrognosisAgedAntineoplastic Agents, HormonalBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedNeoadjuvant TherapyNeoplasm ProteinsNeoplasm Recurrence, LocalReceptors, EstrogenReceptors, ProgesteroneRecurrenceAntineoplastic Agents, HormonalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesNeoplasm ProteinsReceptors, EstrogenReceptors, Progesterone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT00432172ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.